Care of hypertensive patients seen by cardiologists: Results of the Snapshot Hypertension Registry;Der patient mit arterieller hypertonie in der kardiologischen facharztpraxis: Ergebnisse des Snapshot-Hypertonie-Registers - Ein projekt des bundesverbandes niedergelassener kardiologen (BNK e.V.)

Deutsche Medizinische Wochenschrift

Volumn 132, Issue 46, 2007, Pages 2430-2435

  Silber, S ^a   Richartz, B M ^a   Goss, F ^b   Haerer, W ^b   Glowatzki, M ^c   Schmieder, R E ^d  

^a Kardiologische Gemeinschaftspraxis   (Germany)

^b BNK Service GmbH   (Germany)

^c SPSS GmbH Software   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Antihypertensive medication; Blood pressure control; Hypertension; Outcome research; Quality

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; DISEASE REGISTRY; FEMALE; GENERAL PRACTITIONER; HEALTH INSURANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORS; CARDIOLOGY; COMORBIDITY; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; GERMANY; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY ASSURANCE, HEALTH CARE; REFERRAL AND CONSULTATION; REGISTRIES; SEX FACTORS; TREATMENT OUTCOME;

EID: 36749016299     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-991668     Document Type: Article

References (17)

1. ALLHAT Collaborative Research Group. ALLHAT: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Am Med Assoc 2000; 283: 1967-1975
2. Bischoff B, Silber S, Richartz BM, Pieper L, Klotsche J, Wittchen HU. Inadequate medical treatment of patients with coronary artery disease by primary care physicians in Germany. Clin Res Cardiol 2006; 95: 405-12
3. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
4. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906
5. Deutsche Hochdruckliga e.V. - DHL - Deutsche Hypertonie Gesellschaft. Leitlinien zur Diagnostik und Therapie der arteriellen Hypertonie. Nieren und Hochdruckkrankheiten 2005; 34: 481-498
6. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
7. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
8. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553
9. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Hypertens 2007; 25: 1105-87
10. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771
11. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J Am Med Assoc 2004; 292: 2217-2225
12. Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175-1180
13. UK Prospective Diabetes Study Group. UKPDS: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713
14. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007; 167: 141-7
15. Wittchen HU, Glaesmer H, Marz W et al. Cardiovascular risk factors in primary care: methods and baseline prevalence rates - the DETECT program. Curr Med Res Opin 2005; 21: 619-630
16. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781
17. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153